Skip to main content
. 2015 May 6;2015:328078. doi: 10.1155/2015/328078

Figure 3.

Figure 3

Therapies distribution of the 245 (62.3%) anti-dsDNA + (group 1), 52 (13.3%) anti-dsDNA ± (group 2), and 96 (24.4%) anti-dsDNA − (group 3) SLE patients. P = 0.01 group 1 versus group 2 and group 1 versus group 2.